SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is experiencing heightened volatility as investors weigh a strong beat on delivery estimates against concerns over margin compression and a potential 'sell the news' reaction. The community remains deeply divided, with bulls pointing to the record delivery figures and energy storage growth as catalysts for a rally, while bears highlight the high P/E ratio and fears that the market has already priced in the positive news.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is seeing active community debate as investors react to strong delivery guidance and reports of successful production ramps for the R2 model. Traders are closely watching key technical resistance levels while debating whether the current momentum represents a long-term fundamental breakout or a short-term volatility play.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors ramp up pressure on short sellers, fueled by anticipation of upcoming catalysts regarding global expansion and label expansion for their immunotherapy platform. The community is actively discussing the potential for a short squeeze, supported by recent price resilience and widespread optimism that the companys AI-driven manufacturing and NK cell technology are on the verge of significant international adoption.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is seeing significant bullish momentum driven by its successful selection to supply small modular reactors (SMRs) for Sweden, alongside ongoing strength in its defense contracts and aviation engine orders. Community sentiment is overwhelmingly positive, with investors closely watching for mid-year earnings and further major project announcements at upcoming airshows.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending as investors debate whether the current price represents a deep value buying opportunity or a structural decline, fueled by intense community discussion over its high short interest and potential for a massive short squeeze. Shareholders are actively tracking international growth, the Alani Nu brand integration, and market rotation patterns as they wait for an earnings-driven catalyst to spark a reversal.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is currently trending due to active discussions around its growth trajectory, recent international expansion, and comparisons to established brokerage competitors like Robinhood. While some investors are optimistic about potential breakouts driven by platform innovation and institutional accumulation, others remain skeptical, pointing to persistent price volatility and recent performance struggles.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is facing significant selling pressure as investors react to reports of potential hyperscaler competition in the AI compute space, while community sentiment remains heavily polarized due to concerns over executive compensation and a lack of major customer deal announcements. Despite these headwinds, bulls continue to highlight the company's long-term infrastructure assets and power pipeline as a strategic moat in an increasingly compute-constrained market.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as analysts highlight the platform's multi-layered expansion strategy, including global market growth, the launch of Trump-backed investment accounts, and new on-chain financial products. While community sentiment is heavily polarized between bullish supporters betting on long-term platform scale and skeptics wary of high valuations and intense market volatility, the stock remains a central focus for retail traders monitoring institutional upgrades and upcoming corporate events.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is rallying as reports of a potential cloud offering to monetize excess AI compute spark community discussion about the company's ROI on massive capital expenditure. While some investors see this as a strategic move to turn capacity into a revenue stream, others remain skeptical, debating whether this signals a genuine pivot to a neocloud model or an act of desperation following AI overbuild concerns.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending following a surprise announcement of a $350 million convertible senior notes offering, an unexpected move that has sparked investor frustration given the company's existing $2 billion cash balance. While the community is actively debating whether this signals a strategic acquisition, an attempt to bolster the pipeline, or poor capital discipline, many shareholders are expressing deep dissatisfaction with management, citing the stock's long-term underperformance and the lack of clarity regarding the dilution event.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<div><div>Tradr ETFs launches five 2X long ETFs on under-the-radar tech stocksLaunches include first-to-market exposures for quantum upstart QNT and electronic manufacturer TTMINEW YORK, July 1, 2026 /PRNewswire/ -- Tradr&nbsp;ETFs, a provider of ETFs designed for sophisticated investors and professional traders, today launched five new leveraged ETFs on single stocks. The Cboe-listed funds seek to deliver two times long (200%) the daily performance of a specific underlying stock.The following ETFs are expected to open for trading today:<ul><li>Tradr 2X Long CIEN Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4723146-1&amp;h=1365824982&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fciex&amp;a=CIEX">CIEX</a>) – tracks Ciena Corporation (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-introduces-leveraged-etfs-on-ciena-quantinuum-rambus-tower-semiconductor-and-ttm-technologies-302815257.html#financial-modal">CIEN</a>)</li><li>Tradr 2X Long QNT Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4723146-1&amp;h=3114639217&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fqntu&amp;a=QNTU">QNTU</a>) – tracks Quantinuum Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-introduces-leveraged-etfs-on-ciena-quantinuum-rambus-tower-semiconductor-and-ttm-technologies-302815257.html#financial-modal">QNT</a>)</li><li>Tradr 2X Long RMBS Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4723146-1&amp;h=1671861543&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Frmbx&amp;a=RMBX">RMBX</a>) – tracks Rambus Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-introduces-leveraged-etfs-on-ciena-quantinuum-rambus-tower-semiconductor-and-ttm-technologies-302815257.html#financial-modal">RMBS</a>)</li><li>Tradr 2X Long TSEM Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4723146-1&amp;h=667090968&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Ftseu&amp;a=TSEU">TSEU</a>) – tracks Tower Semiconductor Ltd. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-introduces-leveraged-etfs-on-ciena-quantinuum-rambus-tower-semiconductor-and-ttm-technologies-302815257.html#financial-modal">TSEM</a>)</li><li>Tradr 2X Long TTMI Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4723146-1&amp;h=4293316980&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fttmx&amp;a=TTMX">TTMX</a>) – tracks TTM Technologies, Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-introduces-leveraged-etfs-on-ciena-quantinuum-rambus-tower-semiconductor-and-ttm-technologies-302815257.html#financial-modal">TTMI</a>)</li></ul>&nbsp;"The recent market debut of Quantinuum brought renewed enthusiasm to the quantum computing space, one where we already have a strong presence with ETF strategies on Rigetti, D-Wave, QCi and Xanadu," said Matt Markiewicz, Head of Product and Capital Markets at Tradr ETFs. "We are excited to launch first-to-market exposures on not only QNT but TTMI as well, and with networking blue chip CIEN seeing a recent AI-stoked revival, there is a lot of solid momentum around today's launches."Tradr's lineup of 72 leveraged ETFs represents approximately $10 billion in assets under management. Tradr's strategies can be accessed through most brokerage platforms and allow investors to avoid the hassle of using margin and the complexity of options trading. The firm continues its mission of providing sophisticated investors with innovative trading tools that enhance their ability to express market views with precision and efficiency.For detailed information on Tradr ETFs and the significant risks involved with leveraged ETFs, please visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4723146-1&amp;h=4018691999&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a>.About Tradr ETFs <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4723146-1&amp;h=1564732174&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=Tradr+ETFs">Tradr ETFs</a> are designed for sophisticated investors and professional traders who are looking to express high conviction investment views. The strategies include leveraged and inverse ETFs that seek short or long exposure to actively traded stocks and ETFs.IMPORTANT RISK INFORMATIONTradr ETFs are for sophisticated investors and professional traders with high conviction views and are very different from most other ETFs. The Funds are intended to be used as short-term trading vehicles and pursue leveraged investment objectives, which means they are riskier than alternatives that do not use leverage because the Funds magnify the performance of their underlying security. The volatility of the underlying security may affect a Fund's return as much as, or more than, the return of the underlying security.Investors in the fund should: (a) understand the risks associated with the use of leverage; (b) understand the consequences of seeking inverse and leveraged investment results; (c) for short ETFs, understand the risk of shorting; (d) intend to actively monitor and manage their investment. Fund performance will likely be significantly different than the benchmark over periods longer than the specified reset period and the performance may trend in the opposite direction than its benchmark over periods other than that period.Leverage increases the risk of a total loss of an investor's investment, may increase the volatility of the Funds, and may magnify any differences between the performance of the Funds and their reference security. The Funds seek leveraged investment results for a specific period (daily, monthly or quarterly). The exact exposure of an investment in the Fund intra-period will depend upon the movement of the reference security from the end of the prior period until the time of investment by the investor.The Fund will not attempt to position its portfolio to ensure it does not gain or lose more than a maximum percentage of its net asset value on a given trading day. As a consequence, investors in a Fund that seeks two times daily performance would lose all of their money if the Fund's underlying security moves more than 50% in a direction adverse to the Fund on a given trading day.ETFs involve risk including possible loss of the full principal value. There is no assurance that the Fund will achieve its investment objective. Principal risks and other important risks may be found in the prospectus. Past performance does not guarantee future results.ETF shares are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns.Investors should carefully consider the investment objectives, risks, charges and expenses of the Funds. This and other important information about the Fund is contained in the Prospectus, which can be obtained by visiting <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4723146-1&amp;h=4018691999&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a>. The Prospectus should be read carefully before investing.Distributed by ALPS Distributors, Inc, which is not affiliated with AXS Investments or its Tradr ETFs. AXI000981SOURCE Tradr ETFsNote: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.</div></div>

Tradr Introduces Leveraged ETFs on Ciena, Quantinuum, Rambus, Tower Semiconductor and TTM Technologies

Tradr ETFs launches 5 new 2X long leveraged ETFs on CIEN, QNT, RMBS, TSEM & TTMI, including first-to-market exposures on quantum stock QNT and TTMI

Others

Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026Affirms 2026 guidance on key milestonesReports positive CNSide® commercial progressHOUSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company focused on central nervous system (“CNS”) cancers, today provides a comprehensive business update. Notably, the Company announces it is changing its company name from Plus Therapeutics to Cerenome and Nasdaq ticker to CNSY, effective August 3, 2026. Furthermore, the Company affirmed its anticipated 2026 milestones guidance, including commercial guidance around its CNSide Diagnostics business unit.Plus will host a business update conference call and webcast today at 8:30 a.m. Eastern time to discuss the rebranding, progress to milestones and provide additional detail on the Company’s progress for CNSide® Diagnostics. REYOBIQ™, and its artificial intelligence strategy.In connection with the rebrand, the Company expects its common stock to begin trading on Nasdaq under the new ticker symbol&nbsp;“CNSY”. Shareholders are not required to take any action in connection with the anticipated name and ticker change. The Company expects its new corporate website, cerenome.com, to launch in connection with the ticker change.“During the first half of 2026, we remained steadfastly focused on priorities outlined at the beginning of the year, specifically advancing REYOBIQ toward pivotal-trial readiness, scaling CNSide commercialization and building the data infrastructure that inter-connects and fully leverages our therapeutic and diagnostic platforms,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “The Cerenome identity change is the capstone of months of planning reflecting the Company’s current de facto identity as an integrated CNS oncology platform company designed to combine therapeutic interventions, diagnostic insights and advanced data analytics for physicians to improve outcomes for patients with CNS cancers and create long-term value for stockholders.”Business Update Conference Call and Webcast<div><div><figure class="table"><table><tbody><tr><td>Date/Time:</td><td>Tuesday, June 30, 2026 at 8:30 AM ET</td></tr><tr><td>Webcast:</td><td><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=URnFkrNRv6XYl3J7Ofz6nRj_z0qRzFOrxHXuMHbbHqN7ilKoWd-56ni19Pq8E5niHmk7ncv1MO_0D1gCXLBhXbinCo6KriE5kk2aLtQmasW29iMN7YX115vkjGMO4vwvfainB2pfdFLO9s60AmErDA==">Link</a></td></tr><tr><td>Dial-in (U.S./Canada):</td><td>888-349-0106</td></tr><tr><td>Dial-in (International):</td><td>412-317-6789</td></tr></tbody></table></figure></div></div> A replay of the webcast will be available following the event in the Investor Relations section of the Company’s website.Corporate Rebrand to CerenomePlus is introducing the Cerenome corporate identity to better reflect the Company’s integrated CNS oncology strategy. The name combines a reference to the brain with the concept of comprehensive biological and clinical data, aligning with the Company’s focus on CNS cancers and its strategy to integrate therapeutics, diagnostics and proprietary data/AI. The Company also expects to bring the new brand forward more fully to clinicians, partners and the scientific community at the 2026 SNO/ASCO CNS Metastases Conference in August.REYOBIQ Clinical and Manufacturing ProgressREYOBIQ, or rhenium-186 obisbemeda, remains the therapeutic foundation of the Company’s CNS oncology strategy. Plus continues to advance REYOBIQ across leptomeningeal metastases (LM), recurrent glioblastoma (GBM) and pediatric brain cancer (PBC).For 2026, Plus continues to focus on the following priorities:<ul><li>Define the optimal dose and dosing interval for REYOBIQ in the ReSPECT-LM Phase 2 trial</li><li>Continue advancing the ReSPECT-GBM Phase 2 trial toward completion of enrollment and the next regulatory discussion with the U.S. Food and Drug Administration (FDA)</li><li>Complete commercial manufacturing scale-up for REYOBIQ</li><li>Begin enrollment in the ReSPECT-PBC Phase 1 pediatric brain cancer trial</li></ul>In the ReSPECT-LM Phase 2 trial, Plus expects the optimal dose and interval to be consistent with previously released clinical data and believes this may be achieved with 12 to 18 patients, assuming no dose-limiting toxicities, which have not been observed to date. The Company has enrolled approximately one-third of this target and, with ongoing site expansion, may reach a recommended Phase 2 dose by year end.In ReSPECT-GBM, Plus has enrolled 31 of the target 34 subjects. Current enrollment rates support full enrollment in 2026 at 3 active sites. Following completion of the current study and an end-of-Phase 2 meeting with the FDA, the Company believes it may be positioned to move toward a registration study, subject to the final clinical data and related business considerations.Plus also continues to advance commercial manufacturing scale-up for REYOBIQ. Recommendations from the Company’s Type C meeting with the FDA regarding purification qualification and impurity characterization activities have been completed or remain on schedule to be completed by year-end. Method transfer has been initiated, personnel have been trained, qualification activities are progressing to schedule and a Q4 audit is planned for the Company’s new CDMO. The Company has also completed its supply roadmap, including resolution of an overnight delivery constraint with a new vendor.For ReSPECT-PBC, the Company has received both U.S. Department of Defense and Institutional Review Board approval to conduct the pediatric brain cancer study. Contracting with Lurie Children’s Hospital has been completed, site activation is in progress and first dosing is expected in the third quarter of 2026.CNSide Commercial ExpansionPlus reported continued commercial progress for CNSide, the Company’s CSF-based diagnostic platform designed to support the diagnosis and management of patients with CNS cancers. The Company views CNSide as both an independent commercial growth opportunity and a strategic component of its broader CNS oncology platform, with potential applications in patient identification, disease monitoring, longitudinal disease management and clinical trial support.During the first half of 2026, Plus significantly expanded market access, advanced reimbursement infrastructure and increased physician adoption for CNSide. The Company entered the year with approximately 67 million covered lives through United Healthcare and Humana. Following three new commercial coverage agreements year-to-date — Highmark, Blue Shield of California and Elevance Health — total contracted coverage for the CNSide CSF Tumor Cell Enumeration assay now stands at approximately 126 million people. Plus remains on track to achieve its 2026 goal of expanding U.S. commercial payer coverage to more than 150 million covered lives.The Company also advanced the Medicare reimbursement pathway for CNSide. CNSide Diagnostics enrolled in the Medicare program and received its Provider Transaction Access Number (PTAN) on May 7, 2026, enabling the Company to submit claims directly to Medicare. In addition, PLA Code 0640U, CNSide’s dedicated AMA billing identifier, takes effect July 1, 2026. The next milestones in the Medicare pathway include formal Medicare Administrative Contractor coverage determinations and Clinical Lab Fee Schedule pricing for code 0640U.Commercial adoption accelerated during the first half of 2026, supported by expanded payer access, onboarding activity and increasing physician utilization:<ul><li>Year-to-date, 232 CNSide tumor cell enumeration tests have been performed</li><li>June was the highest volume month on record, with 72 CNSide tests performed; based on the growth in test requisitions, the Company expects to achieve a run rate of 1,250 tests per annum by the end of 2026</li><li>18 institutions are onboarded and ordering; 17 additional institutions are in process and approximately 70 individual end-user portal agreements have been signed by healthcare providers and their staffs &nbsp;</li></ul>The Company believes this growing list of enabled institutions, together with expanded payer access and the new PLA code, supports continued adoption of CNSide during the second half of 2026. Furthermore, Plus also remains on schedule to expand the CNSide platform including; three additional families of tests that cover cellular, genomic and phenotypic characterization of CSF specimens in the third quarter of 2026. These assays are intended to expand the clinical data obtained from a single specimen and support clinical decision-making by providers, increasing the economic value of each CSF specimen processed by the Company.Native Data and AI StrategyPlus is implementing its native artificial intelligence strategy intended to become the nervous system of Company’s broader CNS oncology activities.The Company’s initial focus is on building proprietary workflows and data infrastructure that will improve operating efficiency, support clinical and laboratory execution and enable advanced data analytics and machine learning across the company’s proprietary CNS oncology datasets. Longer term, Plus believes this strategy will support real-world evidence generation, disease insights, pipeline expansion and partnership opportunities.In May 2026, Plus entered into an agreement with Ephemeral Technologies to support key components of this data and AI buildout. The Company expects to provide additional updates as this work progresses.About Plus TherapeuticsPlus Therapeutics is a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for CNS cancers. The Company’s lead therapeutic platform is anchored by REYOBIQ™, and its diagnostics strategy includes the CNSide® cerebrospinal fluid assay platform, which is designed to support the management of patients with CNS cancers. Plus is also advancing an integrated data strategy intended to connect therapeutic, diagnostic, and bioinformatic insights across its CNS oncology programs.Forward-Looking StatementsThis press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical operations, expected commercial activities, and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipate,” “intend,” “believe,” “estimate,” “plan,” “will,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the commencement of trading of the Company’s common stock under the new name and ticker; the success of the new rebrand; and, expectations pertaining to 2026 milestones, its platform and its data strategy.The forward-looking statements included in this press release could differ materially from those expressed or implied because of risks, uncertainties, and other factors that include, but are not limited to: receiving required regulatory clearance to commence trading of the Company’s common stock under the new name and ticker; the Company’s ability to maintain regulatory accreditations and certifications; the Company’s ability to successfully commercialize its platform; the Company’s ability to complete its pre-clinical or clinical studies; available cash on hand; the Company’s ability to raise additional capital on reasonable terms or at all; and, changes in local or national economic conditions. This list of risks, uncertainties, and other factors is not complete.Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect the Company’s business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including its annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=7dIuBAG0YNSvLezN-bJYxK6m_gJxBwsgtBPdMaZfbltVJunpgqWK2fMegGV2YmWtSOnh68SNmBMfSUAEhSE-zg==">www.sec.gov</a>. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends, or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.Investor Contact CORE IR <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=D2-1pzKNblWY9MJKgE-ToAxQuUothhwJdmPCp9aBVc4nEJ9aYOaV_xru1kapzEZ032ur-MR8mLQr03J9yC6QRyafC6x-c330dzBewv1alYLXswZMjJF8b6uAk2tPtxhJ">investor@plustherapeutics.com</a> Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding

Plus Therapeutics rebrands to Cerenome (NASDAQ: CNSY) on Aug. 3, affirms 2026 milestones, reports CNSide coverage growth to 126M lives

The appointment of Dr. Ira Wolfson reflects Quantum X Labs' ongoing commitment to building a top global team of scientists working towards a fault tolerant computer, simulations and quantum cyber security &nbsp;Tel Aviv, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- Quantum X Labs Ltd. (Nasdaq: QXL) today announced the appointment of Dr. Ira Wolfson to its leadership team as a quantum researcher, strengthening the Company's scientific and engineering capabilities as it advances the development of next-generation quantum technologies across computing, sensing, and enabling quantum systems.Dr. Wolfson brings decades of multidisciplinary experience spanning advanced physics, complex systems engineering, applied research, and the translation of breakthrough technologies into practical solutions. Throughout his career, he has led high-impact scientific and technological programs, combining deep theoretical expertise with hands-on engineering and product development.At Quantum X Labs, Dr. Wolfson will play a key role in guiding the Company's quantum technology roadmap, contributing to the development of fault tolerant computer, innovative quantum computing architectures, quantum algorithms, quantum sensing technologies, and other strategic initiatives across the Company's expanding portfolio. His expertise will support the integration of advanced scientific research with scalable engineering, helping accelerate the potential commercialization of Quantum X Labs' proprietary technologies."We are delighted to welcome Dr. Ira Wolfson to our leadership team," said Nir Sharon, Chief Quantum Technology Officer of Quantum X Labs. "We believe that his extensive scientific background, leadership experience, and ability to bridge fundamental physics with real-world engineering make him an exceptional addition to Quantum X Labs. As we continue expanding our quantum technology platform, Dr. Wolfson's expertise will strengthen our ability to develop innovative solutions that address some of the most significant challenges in quantum computing and quantum-enabled technologies."Quantum X Labs continues to expand its world-class scientific and engineering organization as it develops technologies designed to address critical challenges in the quantum ecosystem. The Company's research spans multiple areas, including quantum computing architectures, quantum error correction, quantum software, quantum algorithms, photonic and optical technologies, inertial sensing, and other enabling technologies intended to accelerate the commercialization of practical quantum systems.The appointment of Dr. Wolfson reflects Quantum X Labs' ongoing commitment to attracting leading scientific talent and building a multidisciplinary organization capable of delivering transformative innovations across the rapidly evolving quantum technology landscape.Quantum X Labs plans to continue refining its technology, with future work focused on exploring joint ventures and cooperation opportunities for performance optimization, system integration, and scaling toward deployable inertial measurement units (IMUs), fault tolerant computer, simulations and cyber security.Quantum X Labs Inc.Quantum X Labs Inc. and its subsidiaries are focused on quantum technology, digital advertising and computing and enterprise artificial intelligence (AI) solutions. Quantum X Labs Ltd. is focused on developing and promoting quantum algorithms for the transportation, drug discovery and security segments as well as developing quantum- based GPS replacement and quantum atom accuracy solutions. Gix Media develops a variety of technological software solutions, which perform automation, optimization and monetization of internet campaigns, for the purposes of acquiring and routing internet user traffic to its customers. Metagramm is a developer of grammatical error correction software and offers tools for writing and reviewing, grammar, spelling, punctuation and style features, as well as translation and multilingual dictionaries, using artificial intelligence and machine learning technology.For more information about Quantum X Labs, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=b_7C8bxe1DwxU8MpGKKgRHNp12IbULYzBgerJAyhULzN3mcaXioP3G8qhwduyaIQ-ftpAEJIwJM4SGyAcA5UM6F_Gcw-GQ3w-xwXXdrwGq8=">https://quantumxlabs.xyz/</a>Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Quantum X Labs’ and its subsidiaries’ strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses advancing the development of next-generation quantum technologies across computing, sensing, and enabling quantum systems, the anticipated contributions of Dr. Wolfson, the potential commercialization of Quantum X Labs' proprietary technologies, expanding its quantum technology platform, delivering transformative innovations across the rapidly evolving quantum technology landscape and exploring joint ventures and cooperation opportunities. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s most recent Annual Report on 10-K and in subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.Investor Relations Contacts:Michal Efraty Investor Relations <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=MppMfyXDdM6n4DhnR-5VCHSJwL4QLFqJ_0a5NDoB7QSYF5_v8z6VBfvfmBP4KXX-lm7oh29G1ZgFjrBCVnN9MsnB1uIhohPiRKWMkjo05KE=">michal@efraty.com</a>&nbsp;Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Quantum X Labs Appoints Leading Physics Engineering Expert to Advance its Quantum and Fault-Tolerant Quantum Computing Technologies

Quantum X Labs appoints Dr. Ira Wolfson to its leadership team as quantum researcher, strengthening computing and sensing R&D capabilities

PARIS, June 30, 2026 (GLOBE NEWSWIRE) -- Crédit Agricole CIB, the financing and investment banking arm of Crédit Agricole Group, and Pasqal, a global leader in neutral atom quantum computing, announced the signing of a strategic partnership to accelerate the transition from quantum research to operational deployment in capital markets activities.&nbsp;Building on a collaboration initiated in 2019, the partnership enters a new phase focused on the industrialization of quantum computing applications, with initial production use cases targeted as early as 2028.An innovation trajectory validated by concrete resultsSince 2021, Crédit Agricole CIB and Pasqal have conducted several major projects focusing on counterparty credit default risk measurement and portfolio optimization to improve the Bank's capital efficiency. The results indicate that quantum algorithms can, under specific conditions and use cases, improve performance compared to classical approaches for capital markets and risk management applications, supporting the business case for production deployment. The partners believe there may be an opportunity to unlock additional value as quantum hardware and algorithms continue to mature.A clear roadmap to production (2026–2028)The next phase of the partnership will focus on monitoring capital reserve consumption. linked with risk-weighted assets.This roadmap is structured around three activities:<ul><li>Enhanced classical production: Deployment of quantum-inspired algorithms on existing IT infrastructure, aiming to deliver immediate performance improvements without reliance on quantum hardware</li><li>Quantum experimentation: Operational testing on Pasqal’s neutral atom quantum computers to validate real-world performance under production conditions</li><li>Hybrid large-scale deployment: Integration of classical and quantum computing resources with the goal of solving complex problems beyond the reach of today’s systems</li></ul>Structuring the quantum ecosystem: three action leversTo achieve this industrialization, Crédit Agricole CIB is structuring its quantum ecosystem around three pillars: business teams trained in quantum technologies (software and hardware), strategic coordinators ensuring monitoring, and project managers ensuring production deployment. This is supported by access to Pasqal's platforms (simulators and physical machines).“Quantum computing has the potential to establish itself as one of the most structurally transformative technological breakthroughs of the next decade. This partnership marks our transition from an exploratory posture to an industrialization logic. By 2028, we aim to integrate quantum computing into some of our daily operational processes, offering our clients an unprecedented level of performance and precision in portfolio optimization. This ambition fully aligns with our technological innovation strategy and our determination to maintain our leadership in capital markets,” explains Pierre-Olivier Pagnon, Chief Information Officer of Crédit Agricole CIB.“Quantum computing has reached a pivotal moment where its potential is translating into real operational value,” said Wasiq Bokhari, CEO of Pasqal. “Through our long-standing partnership with Crédit Agricole CIB, we are accelerating this shift—combining advanced neutral atom quantum technology with real-world financial use cases to build a clear path toward production-scale deployment. Together, we are laying the foundation for quantum solutions that we believe will redefine optimization and decision-making in capital markets.”Media contacts:Crédit Agricole CIB&nbsp;Paris — Eric Pons +33 (0)6 08 63 03 20 / <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=VlR2K2vCgx65ONsRYUPtVzLEa78hPiQmlaORMWvhXYlbp81wzhtA7EA8kJsq38qFPNxNnDKWI5ud15tfRUnMjwA2TGY-ASsZq5zuuou7Z7M=">eric.pons@ca-cib.com</a>PasqalInvestors: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=6zcTrmcrwk6d2m7HB_WLHT0FCEdaClzAFAKKSiNLnPE8fnK_wwM7tyhAYFjWgSJ4CwfEiHqognyN-0czz0lvoVpMedEK3I1q6I5ZcHbiImA=">investors@pasqal.com</a> Media: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=p3vYXQwVI9e62teCD1jP_xDhHvXRH_oyuOv9H1h2cnpq_7sewfjPVbVkBA27t7eEdpW1G-R-ZfEXW_3aAXvQsQ==">pr@pasqal.com</a>About Crédit Agricole CIBCrédit Agricole CIB is the corporate and investment banking arm of Crédit Agricole Group, the 10th largest banking group worldwide by total assets in 2024 (The Banker, July 2025). With over 10,000 employees across Europe, the Americas, Asia-Pacific, the Middle East, the Bank supports large and mid-cap corporates and institutional clients, helping them meet both local and global financial needs. Crédit Agricole&nbsp;CIB offers a comprehensive range of products and services in capital markets, investment banking, structured finance, commercial banking and international trade. The Bank is a pioneer in climate finance, and a market leader in sustainable finance providing a full spectrum of solutions to all its clients.For more information, please visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=cJmRqms7rMAMaVxVEaEy9nR810lV9q_YKk7qI281nMoXQZdMfadGRSlzXDFgOm-pGaFzHiK-nTco6hoiIpm5EaOeNXBxxkEYyxFKOkE5DJg=">www.ca-cib.com</a><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=8iSd4uO57jPwRLzSld1Jo1FvHzGKxyHeP4XeEgYYgpge93N-_AtEiwfZcyYglv2NydZavOwoQCPCKkRqxmj_7n4jyX8Q2qaP3UhprUbmsV9GdcqpaVwgMdQNtLfWUODY">LinkedIn</a> <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=zEZlvaqq1JOynQkZpJxP8On3Gjnqdrf1h1hBOKO7fccIRu9Kvmrzl-eeODPMc9z4_LxUR4d8GJvvHj9NV-8KEQ==">X</a>About PasqalPasqal is a global leader in delivering practical quantum computing at scale utilizing neutral atom technology and dedicated software for industry, science, and governments. Since its founding in 2019, Pasqal has leveraged Nobel Prize winning research to build high-performance quantum systems and cloud-ready software designed to address complex challenges in optimization, simulation, and artificial intelligence.Headquartered in France, Pasqal employs over 275 people and serves over 25 clients and partners, including Aramco, CMA CGM, OVHcloud, Thales, IBM (Pasqal is part of the IBM Quantum Network), and Sumitomo.Backed by more than USD 300 million in total private funding from leading international investors, Pasqal is pursuing a listing on Nasdaq in partnership with Bleichroeder Acquisition Corp. II (Nasdaq: BBCQ)&nbsp;and is accelerating the adoption of scalable, high-performance quantum computing worldwide.&nbsp;Forward-Looking StatementsCertain statements herein may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “might”, “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “could,” “plan,” “predict,” “project”, “forecast,” “believe,” “potential,” “seem,” “seek,” “target,” “possible,” “future,” “outlook” or similar terminology or expressions that predict or indicate future events or trends. These forward-looking statements include, but are not limited to, statements regarding future events and the proposed business combination between Bleichroeder Acquisition Corp. II (“Bleichroeder”) and Pasqal Holding SAS (“Pasqal”).These statements are based on current expectations and are not predictions of actual performance. They are provided for illustrative purposes only and must not be relied on as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and are beyond the control of Bleichroeder and Pasqal. These statements are subject to known and unknown risks, uncertainties and assumptions regarding Pasqal’s business and the business combination, and actual results may differ materially. These risks and uncertainties include, but are not limited to: general economic, political, social and business conditions; uncertainty or changes with respect to laws and regulations; the inability of the parties to consummate the business combination failure to realize the anticipated benefits of the business combination; the risk that the business combination disrupts Pasqal’s current plans and operations; the risk from Pasqal pursuing an emerging technology, facing significant technical challenges and the potential that it may not achieve commercialization or market acceptance; Pasqal’s reliance on strategic partners and other third parties; Pasqal’s ability to maintain, protect and defend its intellectual property rights; and other risks that will be detailed from time to time in filings with the U.S. Securities and Exchange Commission (the “SEC”). The foregoing list of risk factors is not exhaustive. There may be additional risks that Pasqal and Bleichroeder presently do not know or currently believe are immaterial that could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide Pasqal’s and/or Bleichroeder’s expectations, plans and forecasts of future events and views as of the date of this communication. While Pasqal and/or Bleichroeder may elect to update these forward-looking statements in the future, Pasqal and Bleichroeder specifically disclaim any obligation to do so.Additional Information and Where to Find ItThe business combination will be submitted to shareholders of Bleichroeder for their consideration. In connection with the business combination, Bleichroeder, Bleichroeder Acquisition France Merger Sub 2 and Pasqal jointly filed a registration statement on Form F-4 with the SEC on May 26, 2026 (as subsequently amended, the “Registration Statement”), which included a proxy statement/prospectus and certain other related documents, which serves as both the proxy statement/prospectus to be distributed to Bleichroeder’s shareholders in connection with its solicitation for proxies for the vote by its shareholders in connection with the business combination and other matters described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities to be issued to Pasqal’s shareholders in connection with the completion of the business combination. This communication is not a substitute for the Registration Statement, the definitive proxy statement/prospectus or any other document that Bleichroeder will send to its shareholders in connection with the business combination.BEFORE MAKING ANY INVESTMENT OR VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS AND, IN EACH CASE, ANY AMENDMENTS THERETO, FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION, RELATED TRANSACTIONS AND THE PARTIES TO THE BUSINESS COMBINATION. Investors and security holders may obtain copies of these documents (as and when available) and other documents filed with the SEC free of charge at www.sec.gov.Participants in the SolicitationBleichroeder, Pasqal and certain of their respective directors, executive officers, and other members of management, employees and consultants, under SEC rules, may be deemed participants in the solicitation of proxies from Bleichroeder’s shareholders with respect to the business combination. A list of the names of Bleichroeder’s directors and executive officers and a description of their interests in Bleichroeder and the business combination is contained in the sections entitled “Directors, Executive Officers and Corporate Governance,” “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters,” and “Certain Relationships and Related Transactions, and Director Independence” of the Annual Report filed by Bleichroeder with the SEC on March 16 2026 and the Current Report on Form 8-K filed with the SEC on May 1, 2026, each of which is available free of charge at the SEC’s website at www.sec.gov. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies from Bleichroeder’s shareholders with respect to the business combination, and their direct and indirect interests, is included in the Registration Statement and the proxy statement/prospectus.No Offer or SolicitationThis communication is for informational purposes only and is not (i) an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law nor (ii) the solicitation of any vote in any jurisdiction pursuant to the business combination or otherwise. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or exemptions therefrom. No securities commission or securities regulatory authority has in any way passed upon the merits of the business combination or the accuracy or adequacy of this communication.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Crédit Agricole CIB and Pasqal advance their strategic partnership to deploy quantum computing applied to finance

Crédit Agricole CIB and Pasqal expand their quantum computing partnership, targeting production deployment of quantum algorithms in capital markets by 2028

Derived from first quarter results of CAD $8.3M multiplied by four, it reflects completed DaaS acquisitions contribution and continued drone workflow integration across the company’s portfolio(Vancouver, British Columbia– June 30, 2025) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, today reports that its 2026 annualized revenue run rate is approximately CAD $33 million. This is based on a simple annualized calculation of first quarter 2026 results (the three months ended March 31, 2026) of CAD $8.3 million multiplied by four.“Our first quarter revenue reflects the strength of our DaaS model and the contribution of the acquisitions we have been in the process of integrating over the past year,” said Shaun Passley, Ph.D., ZenaTech CEO. “Annualizing the quarter puts us at roughly CAD $33 million, and we view that as a baseline rather than a ceiling. We have completed several acquisitions during the period, which will contribute a full twelve months of revenue for the first time later in the year.&nbsp; Our DaaS acquisition pipeline remains active, and our recently disclosed Partnership Acquisition Program is progressing with the kind of founder-led, profitable companies we want on the platform.”The annualized revenue run rate is derived by multiplying first-quarter 2026 revenue by four, and is for illustrative purposes only. It is intended to demonstrate the current revenue scale of the Company’s operations following the completion of its DaaS acquisitions. It should not be interpreted as management’s financial guidance or forecast for fiscal 2026.ZenaTech’s primary revenue engine remains the DaaS segment, through which the Company acquires operationally mature but under-digitized service businesses and integrates its ZenaDrone proprietary drone platforms and AI analytics into their workflows. The Company continues to target land survey and geospatial mapping, infrastructure and asset inspection, and exterior building cleaning businesses — sectors where drone-enabled service delivery can provide an immediate productivity advantage. As drone utilization deepens within each portfolio company, ZenaTech anticipates revenue expansion through capacity growth, contract upsell, new drone-derived data product lines, and improved operating margins.Several acquisitions completed during fiscal 2025 and the first half of fiscal 2026 contributed only partial-year revenue in the periods they closed. These businesses are expected to contribute a full twelve-month revenue run rate for the first time during the balance of fiscal 2026.In May 2026, ZenaTech announced a<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenatech.com/zenatech-opens-new-chapter-of-growth-through-partnerships-inviting-founder-led-companies-to-join-its-platform-in-defense-enterprise-saas-and-ai-infrastructure/"> Partnership Acquisition Program</a>, through which the Company is pursuing acquisitions of established, founder-led, profitable businesses in four core verticals: defense technology and unmanned systems, enterprise SaaS and productivity software, AI infrastructure and applied AI, and specialty manufacturing and supply chain. The Company has entered into non-binding letters of intent and term sheets as discussions progress toward potential definitive agreements.About ZenaTech <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenatech.com/">ZenaTech</a>, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform industrial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.droneasaservice.com/?__hstc=67789070.934af5cce603ec4e4de12324e5f9c99d.1781012960112.1782393006281.1782824649929.7&amp;__hssc=67789070.2.1782824649929&amp;__hsfp=ab7e1ff3193b96716daa4ecf5387c6e5"> Drone as a Service</a> (DaaS) business, and a separate enterprise SaaS division of multiple software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries like land surveys and inspections, driving drone-based scalable, recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, and Asia, ZenaTech is advancing AI drones for agriculture and logistics, as well as ISR, cargo, and counter-UAS applications for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&amp;D initiatives.About ZenaDrone ZenaDrone, a subsidiary of ZenaTech, develops and manufactures AI-powered multifunction autonomous drone solutions integrating machine learning, predictive analytics, and advanced computing technologies, for government, defense, and industrial applications. This includes multifunctional drones for surveying, inspections, logistics, security, and defense applications. Its product portfolio under development includes the<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenatech.com/drone-technology-solutions/"> ZenaDrone 1000</a> for ISR defense and specialized cargo, the<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenatech.com/drone-technology-solutions/"> IQ Nano</a> for indoor inventory management and security, the<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenadrone.com/zenadrone-iq-square/?__hstc=67789070.934af5cce603ec4e4de12324e5f9c99d.1781012960112.1782393006281.1782824649929.7&amp;__hssc=67789070.2.1782824649929&amp;__hsfp=ab7e1ff3193b96716daa4ecf5387c6e5"> IQ Square</a> for outdoor inspections and maintenance, the<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenadrone.com/iq-quad-drone/?__hstc=67789070.934af5cce603ec4e4de12324e5f9c99d.1781012960112.1782393006281.1782824649929.7&amp;__hssc=67789070.2.1782824649929&amp;__hsfp=ab7e1ff3193b96716daa4ecf5387c6e5"> IQ Quad</a> for land surveying, and the IQ Aqua, for underwater applications. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing counter-UAS maritime interceptor drones and an integrated defense system.Contacts for more information: Company, Investors and Media:Linda Montgomery ZenaTech 312-241-1415 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:investors@zenatech.com">investors@zenatech.com</a> &nbsp;Investors: Michael Mason CORE IR <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:investors@zenatech.com">investors@zenatech.com</a>Safe Harbor This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements.&nbsp; Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity; ZenaTech’s ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000 and IQ Nano; ZenaTech’s anticipated cash needs and it’s needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months; ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

ZenaTech Reports Annualized Revenue Run Rate of Approximately CAD $33 Million Based on First Quarter 2026 Revenue

ZenaTech reports CAD $33M annualized 2026 revenue run rate, based on Q1's $8.3M x4, driven by DaaS acquisitions and drone workflow integration

Three semi stocks, a networking stalwart and a quantum computing name set to receive the Tradr treatmentNEW YORK, June 26, 2026 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional traders, announced that it expects to launch five single stock leveraged ETFs on Wednesday, July&nbsp;1. The Cboe-listed funds seek to deliver two times (200%) the daily performance of a specific underlying stock.Expected Tradr launches:<ul><li>Tradr 2X Long CIEN Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4720115-1&amp;h=742973724&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fciex&amp;a=CIEX">CIEX</a>) – tracks Ciena Corporation (NYSE: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-to-launch-leveraged-etfs-on-cien-qnt-rmbs-tsem--ttmi-302811176.html#financial-modal">CIEN</a>)</li><li>Tradr 2X Long QNT Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4720115-1&amp;h=3297094587&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fqntu&amp;a=QNTU">QNTU</a>) – tracks Quantinuum Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-to-launch-leveraged-etfs-on-cien-qnt-rmbs-tsem--ttmi-302811176.html#financial-modal">QNT</a>)</li><li>Tradr 2X Long RMBS Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4720115-1&amp;h=512139757&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Frmbx&amp;a=RMBX">RMBX</a>) – tracks Rambus Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-to-launch-leveraged-etfs-on-cien-qnt-rmbs-tsem--ttmi-302811176.html#financial-modal">RMBS</a>)</li><li>Tradr 2X Long TSEM Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4720115-1&amp;h=1524839634&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Ftseu&amp;a=TSEU">TSEU</a>) – tracks Tower Semiconductor Ltd. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-to-launch-leveraged-etfs-on-cien-qnt-rmbs-tsem--ttmi-302811176.html#financial-modal">TSEM</a>)</li><li>Tradr 2X Long TTMI Daily ETF (Cboe: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4720115-1&amp;h=2194073022&amp;u=http%3A%2F%2Fwww.tradretfs.com%2Fttmx&amp;a=TTMX">TTMX</a>) – tracks TTM Technologies, Inc. (Nasdaq: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tradr-to-launch-leveraged-etfs-on-cien-qnt-rmbs-tsem--ttmi-302811176.html#financial-modal">TTMI</a>)</li></ul>For detailed information on Tradr ETFs and the significant risks involved with leveraged ETFs, please visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4720115-1&amp;h=2460511061&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a>.About Tradr ETFs <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4720115-1&amp;h=543416260&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=Tradr+ETFs">Tradr ETFs</a> are designed for sophisticated investors and professional traders who are looking to express high conviction investment views. The strategies include leveraged and inverse ETFs that seek short or long exposure to actively traded stocks and ETFs.IMPORTANT RISK INFORMATIONTradr ETFs are for sophisticated investors and professional traders with high conviction views and are very different from most other ETFs. The Funds are intended to be used as short-term trading vehicles and pursue leveraged investment objectives, which means they are riskier than alternatives that do not use leverage because the Funds magnify the performance of their underlying security. The volatility of the underlying security may affect a Fund's return as much as, or more than, the return of the underlying security.Investors in the fund should: (a) understand the risks associated with the use of leverage; (b) understand the consequences of seeking inverse and leveraged investment results; (c) for short ETFs, understand the risk of shorting; (d) intend to actively monitor and manage their investment. Fund performance will likely be significantly different than the benchmark over periods longer than the specified reset period and the performance may trend in the opposite direction than its benchmark over periods other than that period.Leverage increases the risk of a total loss of an investor's investment, may increase the volatility of the Funds, and may magnify any differences between the performance of the Funds and their reference security. The Funds seek leveraged investment results for a specific period (daily, monthly or quarterly). The exact exposure of an investment in the Fund intra-period will depend upon the movement of the reference security from the end of the prior period until the time of investment by the investor.The Fund will not attempt to position its portfolio to ensure it does not gain or lose more than a maximum percentage of its net asset value on a given trading day. As a consequence, investors in a Fund that seeks two times daily performance would lose all of their money if the Fund's underlying security moves more than 50% in a direction adverse to the Fund on a given trading day.ETFs involve risk including possible loss of the full principal value. There is no assurance that the Fund will achieve its investment objective. Principal risks and other important risks may be found in the prospectus. Past performance does not guarantee future results.ETF shares are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. There can be no guarantee that an active trading market for ETF shares will develop or be maintained, or that their listing will continue or remain unchanged. Buying or selling ETF shares on an exchange may require the payment of brokerage commissions and frequent trading may incur brokerage costs that detract significantly from investment returns.Investors should carefully consider the investment objectives, risks, charges and expenses of the Funds. This and other important information about the Fund is contained in the Prospectus, which can be obtained by visiting <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4720115-1&amp;h=2460511061&amp;u=http%3A%2F%2Fwww.tradretfs.com%2F&amp;a=www.tradretfs.com">www.tradretfs.com</a>. The Prospectus should be read carefully before investing.Distributed by ALPS Distributors, Inc, which is not affiliated with AXS Investments or its Tradr ETFs. AXI000977SOURCE Tradr ETFsNote: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Tradr to Launch Leveraged ETFs on CIEN, QNT, RMBS, TSEM & TTMI

Five new Tradr 2X leveraged ETFs launch July 1 on Cboe, targeting Ciena, Quantinuum, Rambus, Tower Semi, and TTM Technologies

<ul><li>Strategic U.S. Army Partnership: REalloys (NASDAQ-ALOY) has been conditionally selected to operate a long-term Enhanced Use Lease to design, finance, build, and operate heavy rare earth processing facilities at the Tooele Army Depot, Utah as part of the first commercial critical-mineral processing award on a Government military installation, by way of a direct execution of Executive Order 14241.</li></ul>&nbsp;<ul><li>Expedited 2027 Timeline and Cap-Ex Light Approach: Development targeted as early as 2027, with Initial Operating Capability targeted no later than 2028 to align with the January 1, 2027, US federal procurement ban on Chinese materials in the Defense Industrial Manufacturing Base. The partnership is expected to be delivered through an Enhanced Use Lease that is expected to require no taxpayer subsidies.</li></ul>&nbsp;<ul><li>Embedded Long-Term Customer &amp; National Security Defense-Critical Mineral Platform: The planned facilities will refine heavy rare earths, including Dysprosium (“Dy”) &amp; Terbium (“Tb”), which are essential to national security and used in the Defense Industrial Manufacturing Base for high-temperature permanent magnets. These magnets are used in the production of precision-guided munitions, electric motors, sonar and other key systems, solidifying the supply chain partnership between REalloys and the United States Army, Defense Logistics Agency, Department of War, the U.S. Department of Energy, and NASA.</li></ul>&nbsp;<ul><li>Please visit the official United States Army websites for additional information:</li><li><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=rHa4-vL-1olrTdk9cxgskVq7q5r1VGphKPQNzNib0Kry78nCeoKBInbFrzw4yvbB8Z6ZFbF3_yB4VJ9026SN_LV6ebXu9DB82w_SHYnMriA=">https://www.army.mil/sci</a> (Army Strategic Capital Initiatives)</li><li><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=rHa4-vL-1olrTdk9cxgskfw2_ikMHe0jsvmcI3fqd2uMbsF9ALyd0c8DdGSCaNf3F3ElvFnkmNrnnIn40lil7I9ar60gm31GZpjbMEjJrqq-0s1KILJtF7l3n7ZZuSlg">https://www.tooele.army.mil/</a> (U.S. Army Tooele Army Depot)</li><li><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=rHa4-vL-1olrTdk9cxgskVq7q5r1VGphKPQNzNib0KrZDA6TMFBFMiHguq65t3u2s232YGwSKCOESUv043ZE7_ZMLhfA_VV9180nPZTQr7Rmp_9J-AhEYCChBue_LayJzDlkY2-rNWQxQVciAw2Osg==">https://www.army.mil/article/293503</a> &nbsp;</li></ul>EUCLID, Ohio, June 25, 2026 (GLOBE NEWSWIRE) -- REalloys Inc. (NASDAQ: ALOY) (“REalloys” or the “Company”) has been selected by the United States Army to enter into exclusive contract negotiations for a long-term Enhanced Use Lease (“EUL”) to design, finance, build, and operate a critical-mineral processing facilities at the Tooele Army Depot located in Tooele, Utah. Under the contemplated definitive arrangement, REalloys is expected to establish domestic heavy rare earth processing capacity for the heavy rare earth elements that are foundational to the warfighting capability of the U.S. Joint Forces.The award is enacted through the Army’s Strategic Capital Initiatives (SCI), an effort to partner with the private sector to accelerate enterprise-wide modernization. According to the Army, these awards mark the first time the Army has sited commercial mineral-processing facilities on American military installations pursuant to a direct execution of Executive Order 14241. REalloys was named alongside a small group of U.S.-organized industry partners selected to build out domestic processing for minerals the Army has identified as essential to munitions, missiles, sensors, batteries, and the platforms its soldiers depend on.Leonard Sternheim, Chief Executive Officer of REalloys, said:“We believe selection by the U.S. Army for a processing facility on American soil is a powerful validation of REalloys’ mine-to-magnet strategy and of the urgent national need for domestic heavy rare earth capability. Dysprosium and terbium are the heart of the high-temperature magnets that keep our most advanced defense systems running, and today, almost all of that processing happens overseas. We are proud to have the opportunity to help the Army change that, building secure, allied-sourced capacity that supports our Soldiers without putting taxpayer dollars at risk, and doing it ahead of the 2027 deadline our customers are racing to meet.”Why It Matters: Defense-Grade Dysprosium and Terbium:At Tooele, REalloys intends to refine dysprosium (Dy) and terbium (Tb) — heavy rare earth elements that are indispensable to precision guidance and defense electronics. These materials are used to manufacture high-performance permanent magnets capable of withstanding extreme operational temperatures, the kind found in precision-guided munitions, electric motors, and sonar and radar networks. Consistent with REalloys’ strategy, the Company intends to draw on secure, allied feedstock — including Canadian heavy rare earth supply — to feed its downstream separation, metallization, and magnet operations. The facility would extend REalloys’ fully integrated mine-to-magnet strategy further into U.S. soil, complementing the Company’s diversified, allied-nation feedstock base and its downstream processing network. The Company believes domestic processing capacity for Dy and Tb is one of the most strategically scarce links in the Western rare earth supply chain — and a capability the U.S. defense industrial base urgently needs as China-content restrictions take effect.A Proven, Capital-Disciplined Model:The conditional selection is made possible through an Enhanced Use Lease, a statutory authority under 10 U.S.C. § 2667. An EUL is a real-estate agreement that allows the Army to lease non-excess, underutilized land to private-sector partners. Importantly, an EUL is a leasehold — not a land sale — and the United States retains title to the property at all times. Under this structure, the Army acts purely as a landlord, while the private partner bears the costs to finance, design, build, operate, secure, and decommission the facility, putting no taxpayer dollars at risk. In return for use of the land, the partner pays rent at or above fair market value, which the Army prefers to receive as “in-kind” consideration — funding infrastructure improvements that benefit Soldiers, families, and installation operations. A mandatory decommissioning bond ensures funds are secured in advance to return the land to its original condition at lease end. Eligibility was strictly limited to entities organized under U.S. law with majority domestic ownership and control and a U.S. place of business, and any in-kind improvements will adhere to Davis-Bacon prevailing wages and Buy American Act requirements.Positioned Ahead of the 2027 Deadline:Definitive agreements are underway, with development slated to begin as early as 2027 and an Initial Operating Capability targeted no later than 2028. The timing aligns with expanded U.S. federal procurement restrictions on Chinese rare earth content, and reinforces REalloys’ objective of delivering qualified, compliant rare earth metals and alloys to the U.S. Department of Defense, the U.S. Department of Energy, NASA, the U.S. Defense Industrial Base, and the broader U.S. Organic Industrial Base. No construction will begin until rigorous environmental and regulatory reviews — including the National Environmental Policy Act (NEPA), the Clean Air and Water Acts, and all required federal, state, and local permits — are fully complete.General Jack Keane (Ret.), Board Director of Realloys, Commented:“This is an important step for American national security and critical mineral sovereignty. The U.S. Army’s decision to leverage its installations to establish domestic rare earth processing capacity, we believe, is strategically sound and operationally necessary. REalloys’ mine-to-magnet approach, anchored in secure allied feedstocks and a zero-adversary-nexus supply chain, we believe, is well aligned with what the Joint Force needs to help ensure uninterrupted access to the heavy rare earth elements that power our country’s most advanced weapons systems.”Stephen duMont, Chairman of REalloys, Said:“We believe this important activity with the U.S. Army represents a strategic inflection point for REalloys and for the broader effort to establish a sovereign, resilient, and secure heavy rare earth processing capability in the United States. REalloys was purpose-built to give the U.S. government and defense industrial base an onshore and allied-sourced supply of the critical rare earth materials it needs, designed to remove any adversary nexus. We believe being selected to build that capability in partnership with the Army to help revitalize the Organic Industrial Base reflects our shared commitment to ensuring our warfighters have the capability they need to safely perform their mission.”About REalloys Inc.REalloys Inc. (NASDAQ: ALOY) is a U.S.-based rare earth materials company executing a mine-to-magnet strategy across upstream feedstock, midstream separation and metallization, and downstream magnet manufacturing. REalloys is focused on delivering qualified, allied-nation rare earth metals and alloys including dysprosium, terbium, and neodymium to the U.S. Department of Defense, the U.S. Department of Energy, NASA, the U.S. Defense Industrial Base, and the broader U.S. Organic Industrial Base. The Company is headquartered in Boca Raton, Florida, with operational activities centered in Euclid, Ohio.For more information, please visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=-ipOg2OqP_dfIQ6ZAUTlybUHayrQzcnOaOHh3V9gNf3D3OFrKNUgR0vuZcSz0qC95bD-ULYV7gP21xpNJEhGqSpNZTYVBUo82H20rwiwclM=">www.REalloys.com</a> or email <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=B-jcJcmr5o_wPgOLUEov4SaITjBSS_br_gTu8SWGefDhzWZpCPA7t2XgX70HAn6_q41ln-GV8jYwZ6vN-27VNmx8DloZ2fapSQCMDP8G9UGr-yafGqLqbb31gZnJG8q5">InvestInAmerica@REalloys.com</a>.About the U.S. Army Strategic Capital Initiatives (SCI)The Army’s Strategic Capital Initiatives partner with the private sector to accelerate enterprise-wide modernization, including the use of Enhanced Use Leases to establish domestic critical-mineral processing on Army installations. For more information on the Army’s Strategic Capital Initiatives, visit www.army.mil/sci. REalloys’ inclusion is conditional and remains subject to finalization of definitive agreements and completion of required environmental and regulatory reviews.Safe Harbor Clause And Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of applicable securities laws, including statements relating to REalloys’ conditional selection for potential award under DA RFP No. DACA27-9-26-0038000, anticipated timelines, development plans, and expected capabilities. These statements are based on current expectations and assumptions and are subject to risks and uncertainties, including the failure to reach agreement on a final Milestone Table or execute a Business Terms Agreement within the required 90-day period, the failure to execute a final Enhanced Use Lease, the outcome of required environmental and regulatory reviews, and other risks described in REalloys’ filings with the U.S. Securities and Exchange Commission. The conditional selection does not guarantee execution of a final Enhanced Use Lease agreement. REalloys undertakes no obligation to update any forward-looking statements, except as required by applicable law.For a discussion of additional risks and uncertainties that could affect REalloys’ business, financial condition, and results of operations, please refer to REalloys’ filings with the U.S. Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings available at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=ZOUaB3G8_gd6gYCZiGWNwHvtgFneCVe3yGt5DJ80jr6ezDFks_jxCMqWx3gPNu3o_6hyBSGSiIMEr9Ao0EjebQ==">www.sec.gov</a>.Disclosure InformationREalloys uses and intends to continue using its investor website at www.realloys.com as a means of disclosing material non-public information and for complying with Regulation FD. Investors should monitor this site, along with the Company’s press releases, SEC filings, public conference calls, and webcasts.REalloys Inc. Sarah Riley IR and Communications, REalloys <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=F2bQOs7AkmonJoLMkW_0JJ5JfdEXlSoOo-gWC6H29qkvjn5hGQWYszkuwl5vtVe1CyaP30fN4MTxCrhbO6AQqhOjiiuSiMLTRObq_XzefiEAUo6c8z-caWoalYuqnn4n">sarah.riley@realloys.com</a> <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=Jsr7JTohwPyIe8xRV__netkXLxlCVYBx9w-JQMDHNCO_wuivFlxKQUZlZBYmS_t6jkhvbIGbhMRVBFwsd3U8J5s9NJY7vntl37MpDhBz6XY=">www.realloys.com</a>Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

REalloys (NASDAQ: ALOY) Announces Landmark Partnership Agreement with The United States Army & Army’s Strategic Capital Initiatives to Operate Processing Facilities on The Tooele Army Base in Utah

REalloys (ALOY) selected by U.S. Army to build rare earth processing facilities at Tooele Army Depot, targeting operations by 2028

(Vancouver, British Columbia– June 25, 2025) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces the development of a new AI-enabled camera system with integrated LED light illumination for its ZenaDrone IQ Nano autonomous indoor drone platform. Designed and manufactured by the company’s Spider Vision Sensors subsidiary in Taiwan, the new vision system enhances low-light operations to optimize drone-based inventory management, security, inspection, and defense logistics applications. The first prototype units are undergoing testing and evaluation at the Company’s ZenaDrone Sharjah, UAE facility, while an additional 20 to 30 units are currently being produced to support expanded trials and future deployments.“The new camera system further enhances the IQ Nano’s capabilities as a unique AI-powered drone platform driving considerable automation benefits for both commercial and defense customers,” said Dr. Shaun Passley, ZenaTech CEO. “By combining advanced imaging, integrated LED illumination, and AI-driven analytics, we are improving operational visibility, data accuracy, and decision-making in challenging dimly lit indoor warehouse environments. This development supports our strategy of delivering intelligent drone solutions that increase efficiency, reduce costs, and improve mission readiness.”The IQ Nano drone platform is engineered to operate in GPS-denied, confined, and high-risk environments where traditional systems and personnel face operational challenges. The drone platform is designed to automate inventory management by accurately scanning barcodes and tracking assets in warehouses, armories, and logistics facilities, reducing manual labor, minimizing human error, and improving operational safety. Equipped to operate with HD or thermal imaging, autonomous navigation, obstacle avoidance, and AI-powered anomaly detection, the platform also enables secure indoor surveillance of command centers, ammunition depots, and other restricted facilities.The new lightweight 155-gram camera module combines advanced imaging, onboard LED lighting, and AI-powered analytics to improve visibility and data capture in low-light environments. Integrated with the IQ Nano’s software platform, the new vision system is built to enhance asset identification, inventory verification, anomaly detection, and operational reporting, enabling faster and more accurate decision-making for commercial and defense applications.The enhanced IQ Nano platform is designed for commercial and defense applications where speed, precision, and real-time intelligence are critical. In commercial environments, it automates inventory management, asset tracking, inspections, and facility monitoring, while for defense and government users, it supports logistics operations, inventory verification, equipment inspections, and surveillance within secure facilities. AI-powered analytics and low-light imaging enable faster, more accurate data collection and operational decision-making. Designed to operate individually or as part of a coordinated drone fleet, the IQ Nano is built to support simultaneous operations across large or complex facilities.About ZenaTech<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenatech.com/">ZenaTech</a>, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform industrial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.droneasaservice.com/">Drone as a Service</a> (DaaS) business, and a separate enterprise SaaS division of multiple software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries like land surveys and inspections, driving drone-based scalable, recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, and Asia, ZenaTech is advancing AI drones for agriculture and logistics, as well as ISR, cargo, and counter-UAS applications for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&amp;D initiatives.About ZenaDroneZenaDrone, a subsidiary of ZenaTech, develops and manufactures AI-powered multifunction autonomous drone solutions integrating machine learning, predictive analytics, and advanced computing technologies, for government, defense, and industrial applications. This includes multifunctional drones for surveying, inspections, logistics, security, and defense applications. Its product portfolio under development includes the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenatech.com/drone-technology-solutions/">ZenaDrone 1000</a> for ISR defense and specialized cargo, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenatech.com/drone-technology-solutions/">IQ Nano</a> for indoor inventory management and security, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenadrone.com/zenadrone-iq-square/">IQ Square</a> for outdoor inspections and maintenance, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenadrone.com/iq-quad-drone/">IQ Quad</a> for land surveying, and the IQ Aqua, for underwater applications. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing counter-UAS maritime interceptor drones and an integrated defense system.&nbsp;Contacts for more information: Company, Investors, and Media: &nbsp;Linda Montgomery ZenaTech 312-241-1415 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:investors@zenatech.com">investors@zenatech.com</a>Investors: Michael Mason CORE IR <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:investors@zenatech.com">investors@zenatech.com</a>&nbsp;Safe Harbor This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements.&nbsp; Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity; ZenaTech’s ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000, IQ Square, IQ Quad, IQ Aqua, IQ Nano, ZenaDrone 2000, IQ Glider, and Interceptor P-1; ZenaTech’s ability to develop products for markets as currently contemplated; ZenaTech’s anticipated cash needs and it’s needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months; ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech and other related risks ‎‎‎and uncertainties disclosed under the ‎heading “Risk Factors“ ‎‎‎‎in the Company’s Form F-1, Form 20-F and other filings filed ‎‎‎with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=MCJEA-jZovtm7y6ff50FGFHBj5GRIx2tUeuiQgna0unRNYqf61tDuQbFv1jMul2mqArzrhiCgrT7c0s2UFe4WA==">www.sec.gov</a>. The Company undertakes ‎‎‎no obligation to update forward-‎looking ‎‎‎‎information except as required by applicable law. Such forward-‎‎‎looking information represents ‎‎‎‎‎managements’ best judgment based on information currently available. ‎‎‎No forward-looking ‎‎‎‎statement ‎can be guaranteed and actual future results may vary materially. ‎‎‎Accordingly, readers ‎‎‎‎are advised not to ‎place undue reliance on forward-looking statements or ‎‎‎information.‎Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

ZenaTech Advances IQ Nano Indoor Drone Platform with New AI-Enabled LED Camera System for Commercial and Defense Inventory and Security Applications

ZenaTech unveiled an AI-enabled camera with LED lighting for its IQ Nano indoor drone, boosting inventory and security ops in low-light environments

Acquisition strengthens Florida market presence and creates a foundation for scaling AI drone-powered cleaning, inspection and maintenance services in a market growing nearly 17% annuallyVancouver, British Columbia, (June 23, 2026) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions,&nbsp; announces it has closed its 24th acquisition for Drone as a Service with the purchase of Florida-based<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://greenearthpowerwash.com/"> Green Earth Powerwashing LLC</a>, a franchise system with a company-owned operation and franchised units that pay ongoing royalty fees. Founded in 2010 and commencing franchise operations in 2020, the company has a corporate-owned West Palm Beach location and franchisee-operated business locations in central and south Florida. Green Earth provides exterior cleaning and property maintenance services serving local municipal governments and commercial business. The acquisition marks ZenaTech’s eighth acquisition in Florida, strengthening the Company’s footprint while adding a scalable power washing franchise platform to the Drone as a Service network facilitating future expansion opportunities.“The acquisition of Green Earth Powerwashing is another strategic addition to our Drone as a Service business, providing an established customer base, trained operators, and adding to our scalable platform through franchise expertise to accelerate the rollout of drone-powered services,” said Shaun Passley, Ph.D., CEO of ZenaTech. “With more than a decade of recurring business and customer relationships across Florida, Green Earth strengthens our regional footprint and advances our vision of building a first-mover drone-enabled platform in services like cleaning we can automate and scale. As one of the fastest-growing commercial drone segments expanding at nearly 17% annually, we see a significant opportunity for AI drone-powered cleaning to provide faster, safer and more cost-effective automated maintenance solutions for governments, property managers, and commercial building owners across our global network.”Green Earth Powerwashing locations provide exterior cleaning and property maintenance for a variety of property managers, municipalities, commercial property owners, hospitality operators, and homeowners association customers. The company provides pressure washing, roof cleaning, building exterior cleaning, concrete cleaning, and related maintenance services through environmentally responsible cleaning practices and a recurring-service business model. Through its franchise structure, Green Earth has established a platform for geographic expansion while maintaining consistent service standards and customer relationships.ZenaTech management believes there are strong long-term opportunities in major metropolitan markets across the US and globally for Drone as a Service power washing. In Florida, these markets include Miami, Orlando, Tampa, and Fort Lauderdale, where large concentrations of commercial buildings, condominium towers, hotels, and mixed-use developments require regular exterior cleaning and maintenance. By integrating drones into Green Earth’s operations, ZenaTech expects to improve safety, efficiency, service quality, and operating economics, particularly for high-rise and difficult-to-access properties.The global drone power washing market falls under a broader drone cleaning services market category that was valued at approximately USD $5.17 billion in 2024 and is projected to reach over $15.2 billion by 2031, growing at a compound annual growth rate (CAGR) of almost 17% according to market analyst<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://reports.valuates.com/market-reports/QYRE-Auto-38G16768/global-drone-cleaning-service"> Valuates Reports</a>, fueled by increasing demand for safe, efficient and cost-effective maintenance solutions.ZenaTech’s Drone as a Service platform provides business and government clients with subscription-based access to faster and superior drone-based services for a host of surveying, inspection, maintenance, power washing, inventory management, and precision agriculture services, without the costs or operational burdens of drone ownership. By acquiring established, profitable service companies currently using low-tech and under digitized processes ripe for drone innovation, ZenaTech is building a global, multi-service DaaS network of locations in communities anchored by existing customers and revenue, for next-generation drone integration offering speed, precision and safety benefits.About ZenaTech <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenatech.com/">ZenaTech</a>, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform industrial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.droneasaservice.com/?__hstc=67789070.934af5cce603ec4e4de12324e5f9c99d.1781012960112.1781789138916.1782226962800.5&amp;__hssc=67789070.2.1782226962800&amp;__hsfp=ab7e1ff3193b96716daa4ecf5387c6e5"> Drone as a Service</a> (DaaS) business, and a separate enterprise SaaS division of multiple software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries like land surveys and inspections, driving drone-based scalable, recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, and Asia, ZenaTech is advancing AI drones for agriculture and logistics, as well as ISR, cargo, and counter-UAS applications for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&amp;D initiatives.About ZenaDrone ZenaDrone, a subsidiary of ZenaTech, develops and manufactures AI-powered multifunction autonomous drone solutions integrating machine learning, predictive analytics, and advanced computing technologies, for government, defense, and industrial applications. This includes multifunctional drones for surveying, inspections, logistics, security, and defense applications. Its product portfolio under development includes the<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenatech.com/drone-technology-solutions/"> ZenaDrone 1000</a> for ISR defense and specialized cargo, the<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenatech.com/drone-technology-solutions/"> IQ Nano</a> for indoor inventory management and security, the<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenadrone.com/zenadrone-iq-square/?__hstc=67789070.934af5cce603ec4e4de12324e5f9c99d.1781012960112.1781789138916.1782226962800.5&amp;__hssc=67789070.2.1782226962800&amp;__hsfp=ab7e1ff3193b96716daa4ecf5387c6e5"> IQ Square</a> for outdoor inspections and maintenance, the<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.zenadrone.com/iq-quad-drone/?__hstc=67789070.934af5cce603ec4e4de12324e5f9c99d.1781012960112.1781789138916.1782226962800.5&amp;__hssc=67789070.2.1782226962800&amp;__hsfp=ab7e1ff3193b96716daa4ecf5387c6e5"> IQ Quad</a> for land surveying, and the IQ Aqua, for underwater applications. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing counter-UAS maritime interceptor drones and an integrated defense system.Contacts for more information: Company, Investors, and Media:Linda Montgomery ZenaTech 312-241-1415 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:investors@zenatech.com">investors@zenatech.com</a> &nbsp;Investors: Michael Mason CORE IR <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:investors@zenatech.com">investors@zenatech.com</a>Safe Harbor This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements.&nbsp; Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity; ZenaTech’s ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000, IQ Square and IQ Nano; ZenaTech’s ability to develop products for markets as currently contemplated; ZenaTech’s anticipated cash needs and it’s needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months; ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech and other related risks ‎‎‎and uncertainties disclosed under the ‎heading “Risk Factors“ ‎‎‎‎in the Company’s Form F-1, Form 20-F and other filings filed ‎‎‎with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=MCJEA-jZovtm7y6ff50FGFHBj5GRIx2tUeuiQgna0unRNYqf61tDuQbFv1jMul2mqArzrhiCgrT7c0s2UFe4WA==">www.sec.gov</a>. The Company undertakes ‎‎‎no obligation to update forward-‎looking ‎‎‎‎information except as required by applicable law. Such forward-‎‎‎looking information represents ‎‎‎‎‎managements’ best judgment based on information currently available. ‎‎‎No forward-looking ‎‎‎‎statement ‎can be guaranteed and actual future results may vary materially. ‎‎‎Accordingly, readers ‎‎‎‎are advised not to ‎place undue reliance on forward-looking statements or ‎‎‎information.‎Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

ZenaTech Expands Drone as a Service Platform with 24th Acquisition, Adding Green Earth Powerwashing Franchise Network

ZenaTech (Nasdaq: ZENA) acquired Green Earth Powerwashing to scale its AI drone-powered cleaning services across a growing Florida market

Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studiesExtends NeOnc’s UAE footprint beyond NEO212 and complements ongoing U.S. development, where NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designationsCALABASAS, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO100, the Company’s lead candidate, an intranasally administered formulation of purified perillyl alcohol designed for non-invasive nose-to-brain delivery. The authorization covers the Company’s NEO100-01, NEO100-02, and NEO100-03 protocols across Phase 1, Phase 1b, and Phase 2 studies in adults, together with pediatric studies authorized for Phase 1 and Phase 1b pending further protocol review. The authorized indication is progressive or recurrent Grade III or IV gliomas.The breadth of the UAE authorization, spanning three protocols and adult studies from Phase 1 through Phase 2 alongside a defined pediatric pathway, is intended to allow NeOnc to advance multiple stages of clinical development in parallel. The authorization follows the DOH’s recent IND clearance for the Company’s NEO212 program, announced in June 2026, and extends NeOnc’s clinical development footprint in the UAE across both of its lead platforms, the intranasal delivery platform represented by NEO100 and the drug-conjugation platform represented by NEO212.In the United States, NEO100 has received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations, and its lead clinical study, the NEO100-01 Phase 2a trial in recurrent IDH1-mutant high-grade glioma, is fully enrolled.The Company expects to report top-line data from the fully enrolled NEO100-01 Phase 2a trial by the end of July 2026, representing what NeOnc believes may be one of the most important clinical milestones in the Company’s history. Based on the strength of the data observed to date and ongoing interactions with regulators, NeOnc believes the upcoming results may support one or more important regulatory pathways, including potential Breakthrough Therapy designation, expansion of existing Fast Track benefits, and enhanced development opportunities under the program’s existing Orphan Drug designation. While no assurance can be given regarding regulatory outcomes, the Company believes the upcoming data represent a significant milestone in the continued development of NEO100.“This authorization is significant because it comes at a pivotal moment for NeOnc and the NEO100 program,” said Amir Heshmatpour, Chief Executive Officer, Executive Chairman and President of NeOnc. “NEO100 has already received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations, and we are now approaching what we believe could be one of the most important clinical milestones in our Company’s history. We anticipate reporting top-line Phase 2a data by the end of July and believe those results may position NEO100 for additional regulatory opportunities, including potential Breakthrough Therapy designation. If the data continue to reflect the encouraging trends observed to date, we believe NEO100 has the potential to meaningfully alter the treatment paradigm for patients suffering from recurrent high-grade gliomas. While regulatory decisions are ultimately made by the FDA, we are encouraged by the progress of the program and remain focused on bringing a non-invasive treatment option to patients facing devastating brain cancers. Our objective is not simply to advance another oncology drug candidate, but to establish a new paradigm for non-invasive delivery of therapeutics to the brain, potentially changing how CNS diseases are treated worldwide.”“NEO100 uses intranasal delivery to reach the brain directly, a practical route that circumvents the blood-brain barrier without surgery or systemic chemotherapy,” said Thomas Chen, MD, Ph.D., Founder, Chief Medical Officer and Chief Scientific Officer of NeOnc. “Because it is non-invasive, this approach can enable studies in difficult groups, including children with high-grade gliomas that have few options today. An authorization spanning Phase 1 through Phase 2 with a pediatric pathway lets us pursue that work where it is needed most.”The upcoming Phase 2a readout represents the first controlled evaluation of NEO100 in recurrent IDH1-mutant high-grade glioma following encouraging earlier clinical observations. If the study meets its objectives, NeOnc believes the data could support discussions with regulators regarding accelerated development pathways and potentially serve as the foundation for future registrational planning.High-grade gliomas, including WHO Grade III and IV disease, are among the most aggressive brain cancers, with limited treatment options after recurrence. The Company expects to work with healthcare institutions, investigators, and regulatory authorities in the UAE as clinical development activities advance.The UAE authorization further positions NeOnc to rapidly expand clinical development activities internationally as the Company prepares for multiple anticipated regulatory and clinical milestones throughout the second half of 2026.About NeOnc Technologies Holdings, Inc.NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The Company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The Company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.For more about NeOnc and its pioneering technology, visit https://neonc.com.Important Cautions Regarding Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.Please refer to the “Risk Factors” section of our quarterly and annual reports on Form 10-Q and Form 10-K as filed with the Securities and Exchange Commission, along with other cautionary language in those reports and risk factors and other cautionary language in our subsequent filings with the Securities and Exchange Commission, which outline important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the fact that results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials, announced or published data from our clinical trials may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data, and our product candidates are in preclinical and clinical stages of development, are not approved for commercial sale and might never receive regulatory approval or become commercially viable.We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.NEO100™ and NEO212™ are trademarks of NeOnc Technologies Holdings, Inc.Company Contact: info@neonc.comInvestor Contact: Jon Nugent Jon Nugent Communications jon@jonnugent.com 205-566-3026This press release was published by a CLEAR® Verified individual.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

NeOnc received Abu Dhabi IND approval for its brain cancer drug NEO100 across Phase 1 and 2 adult/pediatric studies. Phase 2a data is due July 2026